Eliecer Coto

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11476562/publications.pdf

Version: 2024-02-01

		87888	3	37204	
99	13,106	38		96	
papers	citations	h-index		g-index	
100	100	100		10002	
100	100	100		18083	
all docs	docs citations	times ranked		citing authors	

#	Article	IF	CITATIONS
1	The Renin–Angiotensin–Aldosterone System and Coronavirus Disease 2019. European Cardiology Review, 2021, 16, e07.	2.2	26
2	The APOB polymorphism rs1801701 A/G (p.R3638Q) is an independent risk factor for early-onset coronary artery disease: Data from a Spanish cohort. Nutrition, Metabolism and Cardiovascular Diseases, 2021, 31, 1564-1568.	2.6	0
3	Angiotensin-converting enzymes (ACE, ACE2) gene variants and COVID-19 outcome. Gene, 2020, 762, 145102.	2.2	154
4	Transethnic meta-analysis of rare coding variants in PLCG2, ABI3, and TREM2 supports their general contribution to Alzheimer's disease. Translational Psychiatry, 2019, 9, 55.	4.8	32
5	Gene variants in the NF-KB pathway (NFKB1, NFKBIA, NFKBIZ) and risk for early-onset coronary artery disease. Immunology Letters, 2019, 208, 39-43.	2.5	30
6	Genetic meta-analysis of diagnosed Alzheimer's disease identifies new risk loci and implicates Aβ, tau, immunity and lipid processing. Nature Genetics, 2019, 51, 414-430.	21.4	1,962
7	Distal renal tubular acidosis. Clinical manifestations in patients with different underlying gene mutations. Pediatric Nephrology, 2018, 33, 1523-1529.	1.7	25
8	A new SLC12A3 founder mutation (p.Val647Met) in Gitelman's syndrome patients of Roma ancestry. Nefrologia, 2017, 37, 423-428.	0.4	9
9	A new SLC12A3 founder mutation (p.Val647Met) in Gitelman's syndrome patients of Roma ancestry. Nefrologia, 2017, 37, 423-428.	0.4	3
10	Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease. Nature Genetics, 2017, 49, 1373-1384.	21.4	783
11	Shared genetic contribution to ischemic stroke and Alzheimer's disease. Annals of Neurology, 2016, 79, 739-747.	5.3	56
12	Gitelman syndrome: a review of clinical features, genetic diagnosis and therapeutic management. Expert Opinion on Orphan Drugs, 2016, 4, 1005-1009.	0.8	1
13	MAPT H1 Haplotype is Associated with Late-Onset Alzheimer's Disease Risk in APOE ɛ4 Noncarriers: Results from the Dementia Genetics Spanish Consortium. Journal of Alzheimer's Disease, 2015, 49, 343-352.	2.6	32
14	A labor and cost effective next generation sequencing of PKHD1 in autosomal recessive polycystic kidney disease patients. Gene, 2015, 561, 165-169.	2.2	7
15	The TNFRSF1B rs1061622 polymorphism (p.M196R) is associated with biological drug outcome in Psoriasis patients. Archives of Dermatological Research, 2015, 307, 405-412.	1.9	30
16	Convergent genetic and expression data implicate immunity in Alzheimer's disease. Alzheimer's and Dementia, 2015, 11, 658-671.	0.8	173
17	Evidence of a third ADPKD locus is not supported by re-analysis of designated PKD3 families. Kidney International, 2014, 85, 383-392.	5.2	37
18	The screening of the 3′UTR sequence of LRRK2 identified an association between the rs66737902 polymorphism and Parkinson's disease. Journal of Human Genetics, 2014, 59, 346-348.	2.3	14

#	Article	IF	CITATIONS
19	Mitochondrial DNA haplogroups and risk of new-onset diabetes among tacrolimus-treated renal transplanted patients. Gene, 2014, 538, 195-198.	2.2	19
20	A labor- and cost-effective non-optical semiconductor (Ion Torrent) next-generation sequencing of the SLC12A3 and CLCNKA/B genes in Gitelman's syndrome patients. Journal of Human Genetics, 2014, 59, 376-380.	2.3	15
21	Effect of mitochondrial, <i>APOE. ACE </i> and <i>NOS3 </i> gene polymorphisms on cardiovascular risk factors among the <i>Vaqueiros de Alzada </i> a Northern Spain human isolate. Annals of Human Biology, 2014, 41, 94-97.	1.0	2
22	MiRNA Profile in the Substantia Nigra of Parkinson's Disease and Healthy Subjects. Journal of Molecular Neuroscience, 2014, 54, 830-836.	2.3	58
23	Genetic variation at IL12B, IL23R and IL23A is associated with psoriasis severity, psoriatic arthritis and type 2 diabetes mellitus. Journal of Dermatological Science, 2014, 75, 167-172.	1.9	73
24	Alpha-synuclein transcript isoforms in three different brain regions from Parkinson's disease and healthy subjects in relation to the SNCA rs $356165/rs11931074$ polymorphisms. Neuroscience Letters, 2014, 562, 45-49.	2.1	30
25	Mutation Analysis of the Main Hypertrophic Cardiomyopathy Genes Using Multiplex Amplification and Semiconductor Next-Generation Sequencing. Circulation Journal, 2014, 78, 2963-2971.	1.6	51
26	Gene-Wide Analysis Detects Two New Susceptibility Genes for Alzheimer's Disease. PLoS ONE, 2014, 9, e94661.	2.5	155
27	Profile of microRNAs in the plasma of Parkinson's disease patients and healthy controls. Journal of Neurology, 2013, 260, 1420-1422.	3.6	132
28	Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. Nature Genetics, 2013, 45, 1452-1458.	21.4	3,741
29	The G263X MYBPC3 mutation is a common and low-penetrant mutation for hypertrophic cardiomyopathy in the region of Asturias (Northern Spain). International Journal of Cardiology, 2013, 168, 4555-4556.	1.7	9
30	Association between a MYH9 polymorphism (rs3752462) and renal function in the Spanish RENASTUR cohort. Gene, 2013, 520, 73-76.	2.2	21
31	Resequencing the Whole MYH7 Gene (Including the Intronic, Promoter, and 3′ UTR Sequences) in Hypertrophic Cardiomyopathy. Journal of Molecular Diagnostics, 2012, 14, 518-524.	2.8	20
32	Common European Mitochondrial Haplogroups in the Risk for Psoriasis and Psoriatic Arthritis. Genetic Testing and Molecular Biomarkers, 2012, 16, 621-623.	0.7	11
33	Resequencing of the IL12B gene in psoriasis patients with the rs6887695/rs3212227 risk genotypes. Cytokine, 2012, 60, 27-29.	3.2	15
34	A Search for SNCA 3′ UTR Variants Identified SNP rs356165 as a Determinant of Disease Risk and Onset Age in Parkinson's Disease. Journal of Molecular Neuroscience, 2012, 47, 425-430.	2.3	49
35	Interaction of insulin and PPAR-α genes in Alzheimer's disease: the Epistasis Project. Journal of Neural Transmission, 2012, 119, 473-479.	2.8	20
36	Mitochondrial DNA polymorphisms/haplogroups in hereditary spastic paraplegia. Journal of Neurology, 2012, 259, 246-250.	3.6	9

#	Article	IF	CITATIONS
37	Interactions between PPAR- $\hat{l}\pm$ and inflammation-related cytokine genes on the development of Alzheimer's disease, observed by the Epistasis Project. International Journal of Molecular Epidemiology and Genetics, 2012, 3, 39-47.	0.4	13
38	Role of serotonergic-related systems in suicidal behavior: Data from a case–control association study. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2011, 35, 1518-1524.	4.8	21
39	Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. Nature Genetics, 2011, 43, 429-435.	21.4	1,708
40	Influence of endothelial nitric oxide synthase polymorphisms in psoriasis risk. Archives of Dermatological Research, 2011, 303, 445-449.	1.9	16
41	Replication of <i>MAPT</i> and <i>SNCA</i> , but not <i>PARK16â€18</i> , as susceptibility genes for Parkinson's disease. Movement Disorders, 2011, 26, 819-823.	3.9	64
42	Mitochondrial DNA and TFAM gene variation in early-onset myocardial infarction: Evidence for an association to haplogroup H. Mitochondrion, 2011, 11, 176-181.	3 . 4	29
43	Gitelman syndrome in Gypsy paediatric patients carrying the same intron $9+1~G\>T$ mutation. Clinical features and impact on quality of life. Nephrology Dialysis Transplantation, $2011, 26, 151-155$.	0.7	15
44	Profile of MicroRNAs Differentially Produced in Hearts from Patients with Hypertrophic Cardiomyopathy and Sarcomeric Mutations. Clinical Chemistry, 2011, 57, 1614-1616.	3.2	28
45	Interactions between functional serotonergic polymorphisms and demographic factors influence personality traits in healthy Spanish Caucasians. Psychiatric Genetics, 2010, 20, 171-178.	1.1	19
46	Analysis of the <i>Microâ€RNAâ€133</i> and <i>PITX3</i> genes in Parkinson's disease. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2010, 153B, 1234-1239.	1.7	33
47	Genetic Variation of DKK3 May Modify Renal Disease Severity in ADPKD. Journal of the American Society of Nephrology: JASN, 2010, 21, 1510-1520.	6.1	59
48	Functional polymorphisms in genes of the Angiotensin and Serotonin systems and risk of hypertrophic cardiomyopathy: AT1R as a potential modifier. Journal of Translational Medicine, 2010, 8, 64.	4.4	21
49	Genetic variation at the CCR5/CCR2 gene cluster and risk of psoriasis and psoriatic arthritis. Cytokine, 2010, 50, 114-116.	3.2	22
50	Functional polymorphisms in the CYP3A4, CYP3A5, and CYP21A2 genes in the risk for hypertension in pregnancy. Biochemical and Biophysical Research Communications, 2010, 397, 576-579.	2.1	14
51	Unified Criteria for Ultrasonographic Diagnosis of ADPKD. Journal of the American Society of Nephrology: JASN, 2009, 20, 205-212.	6.1	590
52	Mutation analysis of the myocyte enhancer factor 2A gene (<i>MEF2A</i>) in patients with left ventricular hypertrophy/hypertrophic cardiomyopathy. American Journal of Medical Genetics, Part A, 2009, 149A, 286-289.	1.2	5
53	Mutational screening of the mortalin gene (HSPA9) in Parkinson's disease. Journal of Neural Transmission, 2009, 116, 1289-1293.	2.8	74
54	Mutational screening of the Mitochondrial transcription factors B1 and B2 (TFB1M and TFB2M) in Parkinson's disease. Parkinsonism and Related Disorders, 2009, 15, 468-470.	2.2	4

#	Article	IF	CITATIONS
55	Differential role of serotonergic polymorphisms in alcohol and heroin dependence. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2009, 33, 695-700.	4.8	35
56	Mutations in Sarcomeric Genes MYH7, MYBPC3, TNNT2, TNNI3, and TPM1 in Patients With Hypertrophic Cardiomyopathy. Revista Espanola De Cardiologia (English Ed), 2009, 62, 48-56.	0.6	19
57	Implicación de polimorfismos serotoninérgicos en la gravedad clÃnica del trastorno de pánico. Revista De PsiquiatrÃa Y Salud Mental, 2009, 2, 35-41.	1.8	5
58	Role of serotonergic polymorphisms in the clinical severity of the panic disorder. Revista De PsiquiatrÃa Y Salud Mental (English Edition), 2009, 2, 35-41.	0.3	1
59	Espectro mutacional de los genes sarcoméricos MYH7, MYBPC3, TNNT2, TNNI3 y TPM1 en pacientes con miocardiopatÃa hipertrófica. Revista Espanola De Cardiologia, 2009, 62, 48-56.	1.2	51
60	Pharmacogenetics of Calcineurin Inhibitors in Renal Transplantation. Transplantation, 2009, 88, S62-S67.	1.0	37
61	A search for cyclophilinâ€A gene variants in cyclosporine Aâ€treated renal transplanted patients. Clinical Transplantation, 2008, 22, 722-729.	1.6	17
62	Mitochondrial transcription factor A (TFAM) gene variation in Parkinson's disease. Neuroscience Letters, 2008, 432, 79-82.	2.1	30
63	Association study between obsessive–compulsive disorder and serotonergic candidate genes. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2008, 32, 765-770.	4.8	47
64	Bilineal inheritance of type 1 autosomal dominant polycystic kidney disease (ADPKD) and recurrent fetal loss. CKJ: Clinical Kidney Journal, 2008, 1, 289-291.	2.9	3
65	Association Between the Stin2 VNTR Polymorphism of the Serotonin Transporter Gene and Treatment Outcome in Alcohol-Dependent Patients. Alcohol and Alcoholism, 2008, 43, 516-522.	1.6	26
66	Mitochondrial Transcription Factor A (TFAM) Gene Variation and Risk of Late-Onset Alzheimer's Disease. Journal of Alzheimer's Disease, 2008, 13, 275-280.	2.6	25
67	Association between the A-1438G polymorphism of the serotonin 2A receptor gene and nonimpulsive suicide attempts. Psychiatric Genetics, 2008, 18, 213-218.	1.1	29
68	Mitochondrial Transcription Factors TFA, TFB1 and TFB2: A Search for DNA Variants/Haplotypes and the Risk of Cardiac Hypertrophy. Disease Markers, 2008, 25, 131-139.	1.3	10
69	Association study of serotonin 2A receptor (5-HT2A) and serotonin transporter (5-HTT) gene polymorphisms with schizophrenia. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2007, 31, 741-745.	4.8	38
70	The NOS3 (27-bp repeat, intron 4) polymorphism is associated with susceptibility to osteomyelitis. Nitric Oxide - Biology and Chemistry, 2007, 16, 44-53.	2.7	28
71	Mitochondrial haplogroup T is negatively associated with the status of elite endurance athlete. Mitochondrion, 2007, 7, 354-357.	3.4	52
72	No association between Parkinson's disease and three polymorphisms in the eNOS, nNOS, and iNOS genes. Neuroscience Letters, 2007, 413, 202-205.	2.1	25

#	Article	IF	CITATIONS
73	Prevalence and spectrum of mutations in the sarcomeric troponin T and I genes in a cohort of Spanish cardiac hypertrophy patients. International Journal of Cardiology, 2007, 121, 115-116.	1.7	8
74	Distal RTA with nerve deafness: clinical spectrum and mutational analysis in five children. Pediatric Nephrology, 2007, 22, 825-828.	1.7	37
75	Mitochondrial DNA haplogroups in Spanish patients with hypertrophic cardiomyopathy. International Journal of Cardiology, 2006, 112, 202-206.	1.7	57
76	Haplotype analysis improves molecular diagnostics of autosomal recessive polycystic kidney disease. American Journal of Kidney Diseases, 2005, 45, 77-87.	1.9	41
77	Hypertrophic cardiomyopathy linked to homozygosity for a new mutation in the myosin-binding protein C gene (A627V) suggests a dosage effect. International Journal of Cardiology, 2005, 102, 501-507.	1.7	24
78	Mitochondrial DNA polymorphisms and risk of Parkinson's disease in Spanish population. Journal of the Neurological Sciences, 2005, 236, 49-54.	0.6	97
79	In Vivo Interleukin-6 Protects Neutrophils from Apoptosis in Osteomyelitis. Infection and Immunity, 2004, 72, 3823-3828.	2.2	83
80	A new mutation (intron 9 \pm 1 G>T) in the SLC12A3 gene is linked to Gitelman syndrome in Gypsies. Kidney International, 2004, 65, 25-29.	5.2	59
81	A single-nucleotide polymorphism in the human p27kip1 gene (-838C>A) affects basal promoter activity and the risk of myocardial infarction. BMC Biology, 2004, 2, 5.	3.8	21
82	Chemokines (RANTES and MCP-1) and chemokine-receptors (CCR2 and CCR5) gene polymorphisms in Alzheimer's and Parkinson's disease. Neuroscience Letters, 2004, 370, 151-154.	2.1	65
83	IL-1α (â^' 889) promoter polymorphism is a risk factor for osteomyelitis. , 2003, 119A, 132-136.		35
84	A complete mutation screen of PKHD1 in autosomal-recessive polycystic kidney disease (ARPKD) pedigrees. Kidney International, 2003, 64, 391-403.	5.2	113
85	The T-786C endothelial nitric oxide synthase genotype and coronary artery disease. Journal of the American College of Cardiology, 2003, 42, 1140.	2.8	1
86	Hypertrophic Cardiomyopathy: Low Frequency of Mutations in the \hat{I}^2 -Myosin Heavy Chain (MYH7) and Cardiac Troponin T (TNNT2) Genes among Spanish Patients. Clinical Chemistry, 2003, 49, 1279-1285.	3.2	62
87	Genotype-Renal Function Correlation in Type 2 Autosomal Dominant Polycystic Kidney Disease. Journal of the American Society of Nephrology: JASN, 2003, 14, 1164-1174.	6.1	129
88	Variation in the lipoprotein receptor-related protein, $\hat{l}\pm 2$ -macroglobulin and lipoprotein receptor-associated protein genes in relation to plasma lipid levels and riskof early myocardial infarction. Coronary Artery Disease, 2002, 13, 251-254.	0.7	24
89	Association between the TNFî±-308 A/G polymorphism and the onset-age of Alzheimer disease. American Journal of Medical Genetics Part A, 2002, 114, 574-577.	2.4	69
90	Association between the NOS3 (\hat{a}^{7} 786 T/C) and the ACE (I/D) DNA Genotypes and Early Coronary Artery Disease. Nitric Oxide - Biology and Chemistry, 2001, 5, 343-348.	2.7	81

ELIECER COTO

#	Article	IF	CITATIONS
91	Early-onset Parkinson's disease associated with a new parkin mutation in a Spanish family. Neuroscience Letters, 2001, 313, 108-110.	2.1	17
92	Variation in the LRP-associated protein gene (LRPAP1) is associated with late-onset Alzheimer disease. American Journal of Medical Genetics Part A, 2001, 105, 76-78.	2.4	48
93	Location of mutations within the PKD2 gene influences clinical outcome. Kidney International, 2000, 57, 1444-1451.	5.2	70
94	Genetic variation in the renin-angiotensin system and athletic performance. European Journal of Applied Physiology, 2000, 82, 117-120.	2.5	168
95	Synergistic Effect between Apolipoprotein E and Angiotensinogen Gene Polymorphisms in the Risk for Early Myocardial Infarction. Clinical Chemistry, 2000, 46, 1910-1915.	3.2	65
96	Comparison of phenotypes of polycystic kidney disease types 1 and 2. Lancet, The, 1999, 353, 103-107.	13.7	547
97	Association between an α2 Macroglobulin DNA Polymorphism and Late-Onset Alzheimer's Disease. Biochemical and Biophysical Research Communications, 1999, 264, 48-50.	2.1	48
98	Aberrant Splicing in the PKD2 Gene as a Cause of Polycystic Kidney Disease. Journal of the American Society of Nephrology: JASN, 1999, 10, 2342-2351.	6.1	77
99	Mutational analysis of the CCR5 and CXCR4 genes (HIV-1 co-receptors) in resistance to HIV-1 infection and AIDS development among intravenous drug users. Human Genetics, 1998, 102, 483-486.	3.8	42